Novavax (NVAX)
(Delayed Data from NSDQ)
$12.32 USD
-0.31 (-2.45%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $12.30 -0.02 (-0.16%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.32 USD
-0.31 (-2.45%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $12.30 -0.02 (-0.16%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Zacks News
J&J (JNJ) Starts Phase III Study on RSV Vaccine in Older Adults
by Zacks Equity Research
J&J (JNJ) starts the phase III study on its RSV vaccine candidate in adults aged 60 years and above.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $203.53, moving -0.63% from the previous trading session.
Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.
Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing
by Zacks Equity Research
On being granted the emergency use listing for Novavax's (NVAX) COVID-19 vaccine by WHO, it is to become eligible to supply the same to numerous countries participating through the COVAX facility
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $230.29 in the latest trading session, marking a +1.49% move from the prior day.
Pfizer, Moderna Support COVID Vaccine Booster Before FDA Meet
by Zacks Equity Research
Amid rising coronavirus cases, PFE and MRNA are trying to make booster doses of their COVID-19 vaccine available for US citizens. An FDA meeting is scheduled tomorrow to discuss Comirnaty's booster dose.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $234.29 in the latest trading session, marking a +0.2% move from the prior day.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Novavax (NVAX) Stock Surges YTD as COVID Vaccine Advances Well
by Zacks Equity Research
Upon approval and successful commercialization, Novavax's (NVAX) COVID-19 vaccine should reap huge revenues. The company's other pipeline candidates also show promise.
Novavax (NVAX) Begins Clinical Study on COVID/Flu Combo Jab
by Zacks Equity Research
Novavax (NVAX) starts enrolling patients in a phase I/II study to evaluate a combination of its COVID vaccine and seasonal influenza vaccine.
Pfizer (PFE) Begins Study on RSV Vaccine in Older Adults
by Zacks Equity Research
Pfizer (PFE) starts a phase III study which will evaluate its respiratory syncytial virus vaccine candidate, RSVpreF in adults aged 60 years and above.
3 Large Biotech Stocks Worth Adding to Your Portfolio
by Zacks Equity Research
REGN, MRNA & VRTX are the three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
3 COVID Vaccine Makers to Watch on Pfizer Jab Full FDA Approval
by Zacks Equity Research
Stocks of coronavirus vaccine makers BNTX and MRNA fly high following complete approval of Pfizer's COVID-19 vaccine. The momentum is likely to continue for these stocks. JNJ is another strong contender in this field.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Why Novavax (NVAX) Stock Fell 19% on Friday
by Madeleine Johnson
Shares of the biotech firm plunged 19.6% in Friday trading after it delayed U.S. submission for its Covid-19 vaccine for the third time.
Novavax's (NVAX) Q2 Loss Widens, Revenues Miss, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the second quarter of 2021 while revenues also miss estimates. Shares down in after-hours trading.
Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -26.33% and -19.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming second-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Analysts Estimate Novavax (NVAX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $207.19 in the latest trading session, marking a -1.58% move from the prior day.
5 Best Inverse/Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was subdued last week. A slew of earnings results for the second quarter and a new report on consumer spending for June came in stronger than expected. But increasing cases of the delta variant of COVID-19 also weighed on risk-on sentiments.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $179.14, marking a +0.75% move from the previous day.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $188.59 in the latest trading session, marking a -0.55% move from the prior day.
Moderna (MRNA) Begins Dosing in Study on mRNA Flu Vaccine
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase I/II study on its quadrivalent mRNA-based vaccine candidate, mRNA-1010, against seasonal influenza.